State insurance mandates and off-label use of chemotherapy-Reference-Cited by-同舟云学术

State insurance mandates and off-label use of chemotherapy

Published:2017-07-20 Issue:1 Volume:27 Page:e55-e70
ISSN:1057-9230
Container-title:Health Economics
language:en
Short-container-title:Health Economics

Author:

Smieliauskas Fabrice¹^ORCID,Sharma Hari¹,Hurley Connor²,de Souza Jonas A.³,Shih Ya-Chen Tina⁴

Affiliation:

1. Department of Public Health Sciences; University of Chicago; Chicago IL USA

2. Chicago IL USA

3. Section of Hematology/Oncology, Department of Medicine; University of Chicago; Chicago IL USA

4. Section of Cancer Economics and Policy, Department of Health Services Research; The University of Texas M.D. Anderson Cancer Center; Houston TX USA

Funder

Cancer Research Foundation

American Cancer Society

Agency for Healthcare Research and Quality

Publisher

Wiley

Subject

Health Policy

Reference57 articles.

1. Systematic review: Reliability of compendia methods for off-label oncology indications;Abernethy;Annals of Internal Medicine,2009

2. Association of Community Cancer Centers 2013 Impact of payer coverage and reimbursement policies on off-label use of anticancer therapies

3. Physician survey of impact of payer policies on medically appropriate off-label use;Association of Community Cancer Centers;Oncol. Issues,2014

4. The effects of state mental health parity legislation on perceived quality of insurance coverage, perceived access to care, and use of mental health specialty care;Bao;Health Services Research,2004

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Use of pembrolizumab among older adults with cancer in the United States, before and after FDA approval of its tumor‐agnostic indication;Pharmacoepidemiology and Drug Safety;2023-12-29

2. National Comprehensive Cancer Network Guideline Recommendations of Cancer Drugs With Accelerated Approval;JAMA Network Open;2023-11-14

3. Off-Label Drug Use in Oncology;Creative surgery and oncology;2022-07-16

4. Characteristics and survival of patients with cancer with intended off-label use—a cohort study;BMJ Open;2022-05

5. Childhood cancer drugs in China: An overview and comparison of regulatory approvals in China and the United States;International Journal of Cancer;2021-10-06